Rare Kidney Diseases Market by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule (Small Molecules and Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others)), Route of Administration (Oral, Intravenous, Subcutaneous, and Others) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    October 2022

  • Slides
    95

  • View Count
    608

Example Insights

Rare-Kidney-Disorders-Market-Context-thumb Rare-Kidney-Disorders-Market-Drugs-Targeting-Rare-Kidney-Disorders-thumb Rare-Kidney-Disorders-Market-Distribution-by-Phase-of-Development-thumb
Rare-Kidney-Disorders-Market-Competitiveness-Analysis-thumb Rare-Kidney-Disorders-Market-Partnerships-and-Collaborations-thumb Rare-Kidney-Disorders-Market-Funding-and-Investments-thumb
Rare-Kidney-Disorders-Market-Clinical-Trial-Analysis-thumb Rare-Kidney-Disorders-Market-Clinical-Commercial-Attractiveness-Analysis-thumb Rare-Kidney-Disorders-Market-Distribution-by-Target-Indication-thumb

Overview

The term rare kidney diseases (RKD) represents around 150 different indications. It is worth highlighting that the prevalence rate of rare kidney diseases is estimated to be 60-80 per 100,000 cases / individuals in the US and Europe. Despite their relatively low prevalence, these set of indications are believed to be one of the leading causes of renal diseases, along with diabetes and other rare genetic kidney disease. The low incidence rate of such disorders, coupled to the lack of awareness among the general population, often leads to late or erroneous diagnosis. This, in turn, enables suboptimal therapeutic management, as well as compromised long-term outcomes. The aforementioned factors are some of the key reasons that are believed to be responsible for high mortality rates and severe compromise on chance of survival of a patient suffering with rare kidney diseases. It is worth mentioning that, post the onset of the COVID-19 pandemic, the treatment of patients affected with rare kidney diseases became even more challenging. This can be primarily attributed to the fact that the current treatment options for such indications are heavily reliant on regular patient visits to the hospitals or medical centers. Consequently, during the pandemic, a 30% increase in mortality rate was observed in affected patients. This increase in mortality has compelled players engaged in the pharmaceutical domain to undertake necessary research initiatives in order to identify novel drugs that can efficiently treat rare kidney diseases.

Given the complexity associated with conventional treatment options, such as dialysis, kidney transplant and biopsy, drug developers engaged in this domain have shifted their focus towards the development of drugs that can target a myriad of rare kidney diseases. It is worth highlighting that, since 2020, over seven drugs have received marketing approval for the treatment of rare kidney diseases; these are (in reverse chronological order of approval) Galafold® (Fabry disease, European Medicines Agency (EMA), 2021), Lupkynis™ (Lupus Nephritis (LN), United States Food and Drug Administration (USFDA), 2021), Sibnayal™ (distal Renal Tubular Acidosis (dRTA), EMA, 2021), Tarpeyo® (Immunoglobulin A Nephropathy (IgAN), USFDA, 2021), Benlysta® (LN, USFDA, 2020), Cystadrops® (Cystinosis, USFDA, 2020), and Ultomiris® (Atypical Hemolytic Uremic Syndrome (aHUS), Japan, 2020). Further, more than 90 candidates targeting rare kidney diseases are currently under clinical investigation, while several novel leads are being evaluated in early stages of development. Given the lucrative opportunity associated with these targets, this domain has gained attention of both private and public investors in the past few years. In fact, over USD 4.5 billion has been invested in this domain since 2020. As more candidates are likely to progress towards advanced stages of development, we expect the market to witness aggressive growth in the foreseen future.

Scope of the Report

The Rare Kidney Disease Market by Target Indications (IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy and Others), Type of Molecule (Small Molecules and Biologics (Monoclonal Antibody, Hormone, Recombinant Protein, and Others)), Route of Administration (Oral, Intravenous, Subcutaneous, and Others) and Key Geographies (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecast, 2022-2035 report features an extensive study of the current market landscape and the likely future potential associated with the rare kidney diseases market, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. Amongst other elements, the report features:

  • A detailed executive summary of key insights captured during our research. It offers a high-level view on the current state of rare kidney diseases market and its likely evolution in the mid to long term.
  • A brief introduction to various aspects of rare kidney diseases. It includes a detailed discussion on the historical evolution and factors contributing to the treatment of rare kidney diseases. Further, it highlights various prominent target indications associated with rare kidney diseases, application of omics technology and its future perspectives.
  • A detailed overview of the current market landscape of more than 127  drug candidates that are either approved or currently under development for the treatment of various rare kidney diseases, based on several relevant parameters, such as phase of development (approved, registration, phase III, phase II, phase I, pre-clinical and discovery), target molecule (complement component 5 (C5), complement component 3 (C3), a proliferation-inducing ligand (APRIL), B lymphocyte stimulator (BLyS), Complement Factor B, and others), route of administration (oral, intravenous, subcutaneous, and others), and target indication (complement 3 glomerulopathy (C3G), focal segmental glomerular sclerosis (FSGS), IgA nephropathy (IgAN), lupus nephritis (LN), membranous nephropathy (MN)), type of molecule (biologics and small molecules), and type of biologic (monoclonal antibody (mAb), hormone, recombinant protein, enzyme replacement therapy (ERT), gene therapy, small interfering ribonucleic acid (siRNA) molecule and others). In addition, it presents details of the companies engaged in the development of drugs targeting rare kidney diseases, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, and most active players. 
  • Elaborate profiles of approved and clinical stage drugs indicated for rare kidney diseases (phase II / III or above). Each profile features an overview of the drug developer, clinical trial information related to the drug, clinical trial results, and estimated sales revenues (if available).
  • A detailed competitiveness analysis of companies engaged in the development of rare kidney diseases targeting drugs, based on their developer strength (in terms of years of experience), portfolio strength (in terms of number of drugs developed), and portfolio diversity (in terms of phase of development, target indication, and drug designation). 
  • An in-depth analysis of the various collaborations and partnerships that have been inked by players engaged in the development of drugs targeting various rare kidney diseases since 2017, based on several relevant parameters, such as year of partnership, type of partnership, focus area, type of partner and regional distribution of partnerships. 
  • An analysis of the funding and investments made within the domain, during the period 2016-2022, based on several relevant parameters, such as year of funding, type of funding (seed financing, venture capital financing, debt financing, grants, IPOs and other offerings), leading players (in terms of amount invested) and key investors (in terms of number of funding instances).
  • A detailed clinical trial analysis of ongoing clinical studies for the evaluation of various drug candidates targeting rare kidney diseases, based on several relevant parameters, such as trial registration year, current trial status, phase of development, key target indications, patient age, study design and key geographical regions.  
  • A detailed analysis of the clinical and commercial attractiveness for drugs targeting rare kidney diseases, based on several relevant parameters, such as target patient population, dosing frequency and dose strength.
  • A case study highlighting the companies engaged in offering kidney care services, along with information on their year of establishment, company size (in terms of number of employees), location of headquarters and target indication.

One of the key objectives of this report was to evaluate the current market size and the future potential associated with rare kidney diseases market, over the coming years. We have developed an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across relevant parameters, such as [A] target indications (complement 3 glomerulopathy (C3G), FSGS, IgAN, LN, membranous nephropathy (MN)), [B] type of molecule (small molecules and biologics (monoclonal antibody, hormone, recombinant protein, and others)),[C] route of administration (oral, intravenous, subcutaneous, and others) [D] key geographical regions (North America, Europe, Asia-Pacific, and Rest of the World (RoW)). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of drugs targeting rare kidney diseases? 
  • Which are the key drugs being developed across early and late stages of development?  
  • Who are the key players providing services related to kidney care? 
  • Which are the key indications targeted by drugs indicated for rare kidney diseases? 
  • What type of partnership models are commonly adopted by stakeholders engaged in this domain?
  • Who are the key investors in the domain?
  • Which regions have emerged as the key hubs for conducting clinical studies focused on rare kidney diseases?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. An Overview of rare kidney diseases
3.2. Key Historical Events
3.3. Factors Contributing to rare kidney diseases
3.4. rare kidney diseases: Target Indications
3.5. rare kidney diseases: Applications of Omics Technology
3.6. rare kidney diseases: Future Outlook

4. MARKET LANDSCAPE
4.1. rare kidney diseases: List of Drugs
4.1.1. Analysis by Stage of Development
4.1.2. Analysis by Target Molecule
4.1.3. Analysis by Target Molecule and Route of Administration
4.1.4. Analysis by Target Indication
4.1.5. Analysis by Stage of Development and Target Indication
4.1.6. Analysis by Type of Target Molecule
4.1.7. Analysis by Stage of Development and Type of Target Molecule

4.2. rare kidney diseases: List of Drug Developers
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Region
4.2.4. Most Active Players: Analysis by Number of Drugs

5. DRUG PROFILES
5.1. Benlysta
5.1.1. Company Overview
5.1.2. Drug Overview
5.1.3. Clinical Trial Information
5.1.4. Clinical Trial Results
5.1.5. Estimated Sales Revenue

5.2. Cystadrops®
5.2.1. Company Overview
5.2.2. Drug Overview
5.2.3. Clinical Trial Information
5.2.4. Clinical Trial Results
5.2.5. Estimated Sales Revenue

5.3. Galafold®
5.3.1. Company Overview
5.3.2. Drug Overview
5.3.3. Clinical Trial Information
5.3.4. Clinical Trial Results
5.3.5. Estimated Sales Revenue

5.4. Tarpeyo®
5.4.1. Company Overview
5.4.2. Drug Overview
5.4.3. Clinical Trial Information
5.4.4. Clinical Trial Results
5.4.5. Estimated Sales Revenue

5.5. Ultomiris®
5.5.1. Company Overview
5.5.2. Drug Overview
5.5.3. Clinical Trial Information
5.5.4. Clinical Trial Results
5.5.5. Estimated Sales Revenue

5.6. Thiola®
5.6.1. Company Overview
5.6.2. Drug Overview
5.6.3. Clinical Trial Information
5.6.4. Clinical Trial Results
5.6.5. Estimated Sales Revenue

5.7. Lupkynis™
5.7.1. Company Overview
5.7.2. Drug Overview
5.7.3. Clinical Trial Information
5.7.4. Clinical Trial Results
5.7.5. Estimated Sales Revenue

5.8. Sibnayal™
5.8.1. Company Overview
5.8.2. Drug Overview
5.8.3. Clinical Trial Information
5.8.4. Clinical Trial Results
5.8.5. Estimated Sales Revenue

5.9. Pegunigalsidase Alfa
5.9.1. Company Overview
5.9.2. Drug Overview
5.9.3. Clinical Trial Information
5.9.4. Clinical Trial Results
5.9.5. Estimated Sales Revenue

5.10. Saphnelo™
5.10.1. Company Overview
5.10.2. Drug Overview
5.10.3. Clinical Trial Information
5.10.4. Clinical Trial Results
5.10.5. Estimated Sales Revenue

5.11. Atrasentan
5.11.1. Company Overview
5.11.2. Drug Overview
5.11.3. Clinical Trial Information
5.11.4. Clinical Trial Results
5.11.5. Estimated Sales Revenue

5.12. Bardoxolone Methyl
5.12.1. Company Overview
5.12.2. Drug Overview
5.12.3. Clinical Trial Information
5.12.4. Clinical Trial Results
5.12.5. Estimated Sales Revenue

5.13. Crovalimab
5.13.1. Company Overview
5.13.2. Drug Overview
5.13.3. Clinical Trial Information
5.13.4. Clinical Trial Results
5.13.5. Estimated Sales Revenue

5.14. Ianalumab
5.14.1. Company Overview
5.14.2. Drug Overview
5.14.3. Clinical Trial Information
5.14.4. Estimated Sales Revenue

5.15. Cozaar®
5.15.1. Company Overview
5.15.2. Drug Overview
5.15.3. Clinical Trial Information
5.15.4. Clinical Trial Results
5.15.5. Estimated Sales Revenue

5.16. Cosentyx®
5.16.1. Company Overview
5.16.2. Drug Overview
5.16.3. Clinical Trial Information
5.16.4. Estimated Sales Revenue

5.17. Empaveli®
5.17.1. Company Overview
5.17.2. Drug Overview
5.17.3. Clinical Trial Information
5.17.4. Clinical Trial Results
5.17.5. Estimated Sales Revenue

5.18. Rituxan®
5.18.1. Company Overview
5.18.2. Drug Overview
5.18.3. Clinical Trial Information
5.18.4. Clinical Trial Results
5.18.5. Estimated Sales Revenue

5.19. Sparsentan
5.19.1. Company Overview
5.19.2. Drug Overview
5.19.3. Clinical Trial Information
5.19.4. Clinical Trial Results
5.19.5. Estimated Sales Revenue

5.20. Iptacopan
5.20.1. Company Overview
5.20.2. Drug Overview
5.20.3. Clinical Trial Information
5.20.4. Clinical Trial Results
5.20.5. Estimated Sales Revenue

5.21. Narsoplimab
5.21.1. Company Overview
5.21.2. Drug Overview
5.21.3. Clinical Trial Information
5.21.4. Clinical Trial Results
5.21.5. Estimated Sales Revenue

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Key Methodology and Parameters
6.2. Company Competitiveness Analysis: Biologic Developers (Peer Group 1)
6.3. Company Competitiveness Analysis: Small Molecule Developers (Peer Group 2)

7. PARTNERSHIPS AND COLLABORATIONS
7.1. rare kidney diseases: List of Partnerships
7.2. Analysis by Year of Partnership
7.3. Analysis by Type of Partnership
7.4. Analysis by Year and Type of Partnership
7.5. Analysis by Type of Partnership and Company Size
7.6. Analysis by Target Indication
7.7. Most Active Players: Analysis by Number of Partnerships
7.8. Analysis by Region
7.9. Analysis by Country
7.10. Intercontinental and Intracontinental Agreements

8. FUNDING AND INVESTMENTS
8.1. rare kidney diseases: List of Funding and Investments
8.2. Cumulative Year-wise Trend of Funding, 2016 - 2022
8.3. Analysis of Instances by Type of Funding
8.4. Analysis of Instances by Type of Venture Funding
8.5. Analysis of Instances by Year of Funding and Type of Funding
8.6. Analysis by Type of Funding and Amount Invested
8.7. Analysis of Instances by Type of Investor
8.8. Analysis by Focus Area
8.9. Analysis by Region
8.11. Most Active Investors: Analysis by Number of Instances
8.12. Most Active Players: Analysis by Number of Instances
8.13. Most Active Players: Analysis by Amount Raised (USD Million)

9. CLINICAL TRIAL ANALYSIS
9.1. Methodology and Parameters
9.2. Cumulative Trend by Trial Registration Year, 2016 - 2022
9.3. Analysis by Target Indication
9.4. Analysis by Study Design
9.5. Analysis by Region
9.6. Analysis by Number of Trials, Phase of Development and Region
9.7. Analysis by Patient Age
9.8. Analysis by Trial Registration Year, Number of Trials and Region
9.9. Analysis by Trial Status and Phase of Development
9.10. Analysis of Patients Enrolled by Trial Registration Year
9.11. Analysis of Patients Enrolled by Phase of Development
9.12. Analysis by Number of Trials, Trial Status and Region
9.13. Analysis of Patients Enrolled by Region
9.14. Analysis of Patients Enrolled by Trial Status and Region

10. MARKET FORECAST
10.1. Scope and Limitations
10.2. Key Assumptions and Forecast Methodology
10.3. Global rare kidney diseases Market, 2022-2035

10.4. rare kidney diseases Market: Analysis by Type of Molecule, 2022-2035
10.4.1. rare kidney diseases Market for Biologics, 2022-2035
10.4.2. rare kidney diseases Market for Small Molecules, 2022-2035

10.5. rare kidney diseases Market: Analysis by Route of Administration, 2022-2035
10.5.1. rare kidney diseases Market for Oral Delivery, 2022-2035
10.5.2. rare kidney diseases Market for Intravenous Delivery, 2022-2035
10.5.3. rare kidney diseases Market for Subcutaneous Delivery, 2022-2035
10.5.4. rare kidney diseases Market for Other Delivery Routes, 2022-2035

10.6. rare kidney diseases Market: Analysis by Target Indication, 2022-2035
10.6.1. rare kidney diseases Market for Alport Syndrome, 2022-2035
10.6.2. rare kidney diseases Market for Atypical Hemolytic Uremic Syndrome, 2022-2035
10.6.3. rare kidney diseases Market for C3 Glomerulopathy, 2022-2035
10.6.4. rare kidney diseases Market for Cystinosis, 2022-2035
10.6.5. rare kidney diseases Market for Cystinuria, 2022-2035
10.6.6. rare kidney diseases Market for Dense Deposit Disease, 2022-2035
10.6.7. rare kidney diseases Market for Distal Renal Tubular Acidosis, 2022-2035
10.6.8. rare kidney diseases Market for Fabry Disease, 2022-2035
10.6.9. rare kidney diseases Market for IgA Nephropathy, 2022-2035
10.6.10. rare kidney diseases Market for Lupus Nephritis, 2022-2035
10.6.11. rare kidney diseases Market for Refractory Gout, 2022-2035

10.7. rare kidney diseases Market, 2022-2035: Analysis by Geography
10.7.1. rare kidney diseases Market in North America, 2022-2035
10.7.2. rare kidney diseases Market in Europe, 2022-2035
10.7.3. rare kidney diseases Market in Asia-Pacific, 2022-2035
10.7.4. rare kidney diseases Market in Rest of the World, 2022-2035

11. CLINICAL COMMERCIAL ATTRACTIVENESS
11.1. Scope and Limitations
11.2. Key Assumptions and Methodology
11.3.1. Clinical and Commercial Attractiveness Analysis: Atypical Hemolytic Uremic Syndrome
11.3.2. Clinical and Commercial Attractiveness Analysis: C3 Glomerulopathy
11.3.3. Clinical and Commercial Attractiveness Analysis: Cystinuria
11.3.4. Clinical and Commercial Attractiveness Analysis: Dense Deposit Disease
11.3.5. Clinical and Commercial Attractiveness Analysis: Fabry Disease
11.3.6. Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
11.3.7. Clinical and Commercial Attractiveness Analysis: Lupus Nephritis
11.3.8. Clinical and Commercial Attractiveness Analysis: Refractory Gout
11.3.9. Clinical and Commercial Attractiveness Analysis: Other Target Indications

12. CASE STUDY
12.1. Scope and Key Parameters
12.2. rare kidney diseases: List of Kidney Care Providers
12.3. rare kidney diseases: Advantages of Kidney Care
12.4. rare kidney diseases: Future Perspectives
12.5. rare kidney diseases: Approach for Recent Initiatives

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 rare kidney diseases: Executive Summary
Figure 3.1 Key Historical Events
Figure 3.2 Factors Contributing to rare kidney diseases
Figure 3.3 rare kidney diseases: Target Indications
Figure 3.4 rare kidney diseases: Applications of Omics Technology
Figure 3.5 rare kidney diseases: Future Outlook
Figure 4.1 rare kidney diseases: Distribution by Stage of Development
Figure 4.2 rare kidney diseases: Distribution by Target Molecule
Figure 4.3 rare kidney diseases: Distribution by Type of Target Molecule and Route of Administration
Figure 4.4 rare kidney diseases: Distribution by Target Indication
Figure 4.5 rare kidney diseases: Distribution by Stage of Development and Target Indication
Figure 4.6 rare kidney diseases: Distribution by Type of Target Molecule
Figure 4.7 rare kidney diseases: Distribution by Stage of Development and Type of Target Molecule
Figure 4.8 rare kidney diseases: Distribution by Year of Establishment
Figure 4.9 rare kidney diseases: Distribution by Company Size
Figure 4.10 rare kidney diseases: Distribution by Region
Figure 4.11 Most Active Players: Analysis by Number of Drugs
Figure 5.1 Benlysta: Estimated Sales Revenue
Figure 5.2 Cystadrops®: Estimated Sales Revenue
Figure 5.3 Galafold®: Estimated Sales Revenue
Figure 5.4 Tarpeyo®: Estimated Sales Revenue
Figure 5.5 Ultomiris®: Estimated Sales Revenue
Figure 5.6 Thiola®: Estimated Sales Revenue
Figure 5.7 Lupkynis™: Estimated Sales Revenue
Figure 5.8 Sibnayal™: Estimated Sales Revenue
Figure 5.9 Pegunigalsidase Alfa: Estimated Sales Revenue
Figure 5.10 Saphnelo™: Estimated Sales Revenue
Figure 5.11 Atrasentan: Estimated Sales Revenue
Figure 5.12 Bardoxolone Methyl: Estimated Sales Revenue
Figure 5.13 Crovalimab: Estimated Sales Revenue
Figure 5.14 Ianalumab: Estimated Sales Revenue
Figure 5.15 Cozaar®: Estimated Sales Revenue
Figure 5.16 Cosentyx®: Estimated Sales Revenue
Figure 5.17 Empaveli®: Estimated Sales Revenue
Figure 5.18 Rituxan®: Estimated Sales Revenue
Figure 5.19 Sparsentan: Estimated Sales Revenue
Figure 5.20 Iptacopan: Estimated Sales Revenue
Figure 5.21 Narsoplimab: Estimated Sales Revenue
Figure 6.1 Company Competitiveness Analysis (Peer Group I): Biologic Developers
Figure 6.2 Company Competitiveness Analysis (Peer Group II): Small Molecules Developers
Figure 7.1 Partnership Analysis: Distribution by Year of Partnership
Figure 7.2 Partnership Analysis: Distribution by Type of Partnership
Figure 7.3 Partnership Analysis: Distribution by Year and Type of Partnership
Figure 7.4 Partnership Analysis: Distribution by Type of Partnership and Company Size
Figure 7.5 Partnership Analysis: Distribution by Target Indication
Figure 7.6 Most Active Players: Distribution by Number of Partnerships
Figure 7.7 Partnership Analysis: Regional Distribution
Figure 7.8 Partnership Analysis: Country-Wise Distribution
Figure 7.9 Partnership Analysis: Intercontinental and Intracontinental Agreements
Figure 8.1 Funding and Investments: Cumulative Distribution of Amount Invested by Year
Figure 8.2 Funding and Investments: Distribution of Instances by Type of Funding
Figure 8.3 Funding and Investments: Distribution of Instances by Type of Venture Funding
Figure 8.4 Funding and Investments: Distribution by Year and Type of Funding
Figure 8.5 Funding and Investments: Distribution of Instances by Type of Funding
Figure 8.6 Funding and Investments: Distribution of Instances by Type of Investor
Figure 8.7 Funding and Investments: Distribution by Amount Invested and Type of Molecule (USD Million)
Figure 8.8 Funding and Investments: Distribution by Focus Area
Figure 8.9 Funding and Investments: Distribution by Geography
Figure 8.10 Funding and Investments: Distribution by Amount Invested (USD Million) and Region (USD Million)
Figure 8.11 Most Active Investors: Analysis by Number of Instances
Figure 8.12 Most Active Players: Analysis by Number of Instances
Figure 8.13 Most Active Players: Analysis by Amount Raised (USD Million)
Figure 9.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year
Figure 9.2 Clinical Trial Analysis: Distribution by Target Indication
Figure 9.3 Clinical Trial Analysis: Distribution by Study Design
Figure 9.4 Clinical Trial Analysis: Distribution by Region
Figure 9.5 Clinical Trial Analysis: Distribution by Number of Trials, Phase of Development and Region
Figure 9.6 Clinical Trial Analysis: Distribution by Patient Age
Figure 9.7 Clinical Trial Analysis: Distribution by Trial Registration Year, Number of Trials and Region
Figure 9.8 Clinical Trial Analysis: Distribution by Trial Status and Phase of Development
Figure 9.9 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Registration Year
Figure 9.10 Clinical Trial Analysis: Distribution of Patients Enrolled by Phase of Development
Figure 9.11 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Region
Figure 9.12 Clinical Trial Analysis: Patients Enrolled by Region
Figure 9.13 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Region
Figure 10.1 Global rare kidney diseases Market, 2022-2035 (USD Million)
Figure 10.2 rare kidney diseases Market: Distribution by Type of Molecule, 2022 and 2035
Figure 10.3 rare kidney diseases Market for Biologics, 2022-2035 (USD Million)
Figure 10.4 rare kidney diseases Market for Small Molecules, 2022-2035 (USD Million)
Figure 10.5 rare kidney diseases Market: Distribution by Route of Administration, 2022 and 2035
Figure 10.6 rare kidney diseases Market for Oral Delivery, 2022-2035 (USD Million)
Figure 10.7 rare kidney diseases Market for Intravenous Delivery, 2022-2035 (USD Million)
Figure 10.8 rare kidney diseases Market for Subcutaneous Delivery, 2022-2035 (USD Million)
Figure 10.9 rare kidney diseases Market for Other Delivery Routes, 2022-2035 (USD Million)
Figure 10.10 rare kidney diseases Market: Distribution by Target Indications, 2022 and 2035
Figure 10.11 rare kidney diseases Market for Alport Syndrome, 2022-2035 (USD Million)
Figure 10.12 rare kidney diseases Market for Atypical Hemolytic Uremic Syndrome, 2022-2035 (USD Million)
Figure 10.13 rare kidney diseases Market for C3 Glomerulopathy, 2022-2035 (USD Million)
Figure 10.14 rare kidney diseases Market for Cystinosis, 2022-2035 (USD Million)
Figure 10.15 rare kidney diseases Market for Cystinuria, 2022-2035 (USD Million)
Figure 10.16 rare kidney diseases Market for Dense Deposit Disease, 2022-2035 (USD Million)
Figure 10.17 rare kidney diseases Market for distal Renal Tubular Acidosis, 2022-2035 (USD Million)
Figure 10.18 rare kidney diseases Market for Fabry Disease, 2022-2035 (USD Million)
Figure 10.19 rare kidney diseases Market for IgA Nephropathy, 2022-2035 (USD Million)
Figure 10.20 rare kidney diseases Market for Lupus Nephritis, 2022-2035 (USD Million)
Figure 10.21 rare kidney diseases Market for Refractory Gout, 2022-2035 (USD Million)
Figure 10.22 rare kidney diseases Market: Distribution by Geography, 2022 and 2035
Figure 10.23 rare kidney diseases Market in North America, 2022-2035 (USD Million)
Figure 10.24 rare kidney diseases Market in Europe, 2022-2035 (USD Million)
Figure 10.25 rare kidney diseases Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 10.26 rare kidney diseases Market in Rest of the World, 2022-2035 (USD Million)
Figure 11.1 Clinical and Commercial Attractiveness Analysis: Atypical Hemolytic Uremic Syndrome
Figure 11.2 Clinical and Commercial Attractiveness Analysis: C3 Glomerulopathy
Figure 11.3 Clinical and Commercial Attractiveness Analysis: Cystinuria
Figure 11.4 Clinical and Commercial Attractiveness Analysis: Dense Deposit Disease
Figure 11.5 Clinical and Commercial Attractiveness Analysis: Fabry Disease
Figure 11.6 Clinical and Commercial Attractiveness Analysis: IgA Nephropathy
Figure 11.7 Clinical and Commercial Attractiveness Analysis: Lupus Nephritis
Figure 11.8 Clinical and Commercial Attractiveness Analysis: Refractory Gout
Figure 11.9 Clinical and Commercial Attractiveness Analysis: Other Target Indications

List Of Tables

Table 3.1 rare kidney diseases: List of Drugs
Table 4.1 rare kidney diseases: List of Drugs
Table 4.2 rare kidney diseases: List of Drug Developers
Table 5.1 Benlysta: Clinical Trial Information
Table 5.2 Cystadrops®: Clinical Trial Information
Table 5.3 Galafold®: Clinical Trial Information
Table 5.4 Tarpeyo®: Clinical Trial Information
Table 5.5 Ultomiris®: Clinical Trial Information
Table 5.6 Thiola®: Clinical Trial Information
Table 5.7 Lupkynis™: Clinical Trial Information
Table 5.8 Sibnayal™: Clinical Trial Information
Table 5.9 Pegunigalsidase Alfa: Clinical Trial Information
Table 5.10 Saphnelo™: Clinical Trial Information
Table 5.11 Atrasentan: Clinical Trial Information
Table 5.12 Bardoxolone Methyl: Clinical Trial Information
Table 5.13 Crovalimab: Clinical Trial Information
Table 5.14 Ianalumab: Clinical Trial Information
Table 5.15 Cozaar®: Clinical Trial Information
Table 5.16 Cosentyx®: Clinical Trial Information
Table 5.17 Empaveli®: Clinical Trial Information
Table 5.18 Rituxan®: Clinical Trial Information
Table 5.19 Sparsentan: Clinical Trial Information
Table 5.20 Iptacopan: Clinical Trial Information
Table 5.21 Narsoplimab: Clinical Trial Information
Table 7.1 rare kidney diseases: List of Partnerships and Collaborations
Table 8.1 rare kidney diseases: List of Funding and Investments
Table 12.1 rare kidney diseases: List of Kidney Care Companies

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report:

  1. AbbVie
  2. Achillion Pharmaceuticals
  3. Aduro Biotech
  4. Advicenne
  5. Aevitas Therapeutics (A subsidiary of Fortress Biotech)
  6. Alexion Pharmaceuticals (A subsidiary of AstraZeneca)
  7. Algomedix
  8. Alnylam Pharmaceuticals
  9. Amicus Therapeutics
  10. Amyndas Pharmaceuticals
  11. Anelixis Therapeutics (Acquired by Eledon Pharmaceuticals)
  12. Apellis Pharmaceuticals
  13. Apple Tree Partners
  14. Arrowhead Pharmaceuticals
  15. ARYA Sciences Acquisition
  16. Asahi Kasei Pharma
  17. Astellas Pharma
  18. AstraZeneca
  19. Aurinia Pharmaceuticals
  20. AVROBIO
  21. Beam Therapeutics
  22. BioCryst Pharmaceuticals
  23. Biogen
  24. Boehringer Ingelheim
  25. Bristol-Myers Squibb
  26. Calliditas Therapeutics
  27. ChemoCentryx
  28. CHIESI Farmaceutici
  29. Chinook Therapeutics
  30. Cian Healthcare
  31. Complexa
  32. Cormorant Asset Management
  33. Dicerna Pharmaceuticals
  34. EcoR1 Capital
  35. Eledon Pharmaceuticals (Formerly known as Novus Therapeutics)
  36. Ember Therapeutics
  37. Evotec
  38. ExCEEd Orphan
  39. Foresee Pharmaceuticals
  40. Frazier Healthcare Partners
  41. FrostPharma
  42. Fulcrum Therapeutics
  43. GENERIUM
  44. Gilead Sciences
  45. GlaxoSmithKline
  46. Goldfinch Bio
  47. Grifols
  48. Halozyme Therapeutics
  49. Horizon Pharma
  50. Horizon Therapeutics
  51. Idorsia Pharmaceuticals
  52. I-Mab Biopharma
  53. InflamaCORE
  54. Ionis Pharmaceuticals
  55. Jiangsu Hengrui Medicine
  56. Kezar Life Sciences
  57. Lonza
  58. Mallinckrodt Pharmaceuticals
  59. MedImmune
  60. Monashee Investment Management
  61. Morehouse School of Medicine
  62. Morningside 
  63. MorphoSys
  64. myTomorrows
  65. Novartis Pharmaceuticals
  66. Omeros
  67. Oraxion Therapeutics (A subsidiary of Aten Porus Lifesciences)
  68. Organon
  69. Orphan Technologies
  70. Otsuka Pharmaceutical
  71. Pfizer
  72. Pivotal bioVenture Partners 
  73. Protalix Biotherapeutics
  74. Reata Pharmaceuticals
  75. Recordati Rare Diseases
  76. Regulus Pharmaceuticals
  77. RemeGen Biosciences
  78. Rigel Pharmaceuticals
  79. Roche 
  80. ROHTO Pharmaceutical
  81. Samsara BioCapital
  82. Sanofi
  83. Savient Pharmaceuticals
  84. Silence Therapeutics
  85. Surveyor Capital
  86. Swedish Orphan Biovitrum (SOBI)
  87. Syntimmune
  88. Takeda
  89. Travere Therapeutics (Formerly known as Retrophin)
  90. TwinPharma
  91. University of Massachusetts Medical School
  92. University of Pennsylvania
  93. University of Washington
  94. Vera Therapeutics
  95. Vifor Pharma
  96. Visterra (Acquired by Otsuka Pharmaceutical)
  97. Zealand Pharma
  98. ZyVersa Therapeutics (Formerly known as Variant Pharmaceuticals)

Segmentation

Market Segments Details

Forecast Period

  • 2022 – 2035

Target Indications

  • Oncological disorders
  • IgA Nephropathy
  • Lupus Nephritis
  • Focal Segmental Glomerular Sclerosis
  • Membranous Nephropathy
  • C3 Glomerulopathy
  • Other Disorders

Type of Molecule

  • Small Molecules
  • Biologics

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous
  • Others

Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • MENA
  • Latin America
  • Rest of the World 

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com